PSP and CBS Biomarker Validation Study

PSP CBS Biomarker Validation

Overview

This experiment aims to validate a multimodal biomarker panel for early diagnosis, disease progression monitoring, and therapeutic response prediction in Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Currently, there are no validated biomarkers for these 4R-tauopathies, making differential diagnosis challenging and clinical trial enrollment inefficient.

Hypothesis

Primary Hypothesis: A combination of fluid biomarkers ([NfL](/biomarkers/neurofilament-light-chain-nfl), p-tau181, p-tau217), [imaging biomarkers](/biomarkers/tau-pet-cbs-psp) (tau PET, MRI atrophy patterns), and [genetic markers](/mechanisms/cbs-psp-genetic-architecture) will achieve ≥90% sensitivity and specificity for distinguishing PSP/CBS from other neurodegenerative diseases.

Secondary Hypothesis: Baseline biomarker levels will predict disease progression rate and treatment response in clinical trials.

Background

Current challenges in PSP/CBS diagnosis and monitoring:

• Clinical diagnosis relies on symptom presence, often delaying accurate diagnosis by 2-3 years
• No validated biomarkers for differential diagnosis
• Clinical trial endpoints are insensitive to early disease changes
• Patient stratification for clinical trials is suboptimal

PSP CBS Biomarker Validation

Overview

This experiment aims to validate a multimodal biomarker panel for early diagnosis, disease progression monitoring, and therapeutic response prediction in Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Currently, there are no validated biomarkers for these 4R-tauopathies, making differential diagnosis challenging and clinical trial enrollment inefficient.

Hypothesis

Primary Hypothesis: A combination of fluid biomarkers ([NfL](/biomarkers/neurofilament-light-chain-nfl), p-tau181, p-tau217), [imaging biomarkers](/biomarkers/tau-pet-cbs-psp) (tau PET, MRI atrophy patterns), and [genetic markers](/mechanisms/cbs-psp-genetic-architecture) will achieve ≥90% sensitivity and specificity for distinguishing PSP/CBS from other neurodegenerative diseases.

Secondary Hypothesis: Baseline biomarker levels will predict disease progression rate and treatment response in clinical trials.

Background

Current challenges in PSP/CBS diagnosis and monitoring:

• Clinical diagnosis relies on symptom presence, often delaying accurate diagnosis by 2-3 years
• No validated biomarkers for differential diagnosis
• Clinical trial endpoints are insensitive to early disease changes
• Patient stratification for clinical trials is suboptimal

• [Neurofilament light chain (NfL)](https://pubmed.ncbi.nlm.nih.gov/): Elevated in PSP/CBS, correlates with disease severity
• [p-tau181 and p-tau217](/biomarkers/cbs-psp-plasma-biomarkers): Potential tau-specific markers
• [MRI atrophy patterns](/biomarkers/mri-atrophy-cbs-psp): Midbrain, superior cerebellar peduncle
• [Tau PET](/biomarkers/tau-pet-cbs-psp): Emerging 4R-tau ligands (PI-2620)
• [CSF biomarkers](/biomarkers/cbs-psp-csf-biomarkers): 4R-tau specific assays

Detailed Protocol

Study Design

• Type: Prospective, multi-center, longitudinal cohort
• Duration: 36 months
• Sample Size: 300 participants
• PSP (n=120, Richardson syndrome and variants)
• CBS (n=80)
• [Parkinson's disease](/diseases/parkinsons-disease) (n=50, disease control)
• Healthy controls (n=50)

Inclusion Criteria

• Age 50-80 years
• Possible or probable PSP (MDS-PSP criteria) or CBS (Cambridge criteria)
• MMSE ≥ 20
• Ability to undergo MRI and lumbar puncture

Biomarker Assessment

Fluid Biomarkers (every 6 months)

• Plasma and CSF NfL (Simoa)
• Plasma and CSF p-tau181, [p-tau217](/biomarkers/p-tau-217) (Lumipulse)
• Plasma and CSF total tau
• Neurogranin (synaptic marker)
• [Alpha-synuclein](/proteins/alpha-synuclein) seeding assay
• 4R-tau specific assays (developing)

Imaging Biomarkers (baseline, 12, 24, 36 months)

• MRI: 3D T1, T2/FLAIR, DTI
• Volumetry: midbrain, pons, SCP, basal ganglia
• Diffusion: white matter tract integrity
• Tau PET: 4R-selective tracer (PI-2620 or successor)
• Regional SUVR binding
• Kinetic modeling

Genetic Biomarkers (baseline)

• [MAPT](/proteins/tau) H1/H2 haplotype
• Known PSP/CBS risk variants ([C9orf72](/entities/c9orf72), etc.)
• Polygenic risk score

Clinical Assessments (every 6 months)

• PSP Rating Scale (PSPRS)
• MDS-UPDRS
• Mini-Mental State Examination
• Frontal Assessment Battery
• Montreal Cognitive Assessment
• Quality of life measures (PSP-QoL, PDQ-39)

Reagents and Equipment

| Item | Supplier | Cost (USD) |
|------|----------|-------------|
| NfL Simoa assay kit | Quanterix | $85,000 |
| p-tau181/217 Lumipulse kits | Fujirebio | $120,000 |
| Tau PET tracer (PI-2620) | Avid/Gray Matter | $250,000 |
| MRI scanning (per session) | Multi-site | $300,000 |
| CSF collection supplies | Qiagen/Sarstedt | $15,000 |
| Genetic sequencing | Illumina | $40,000 |
| Bioinformatics infrastructure | In-house | $50,000 |
| Clinical coordination | Multi-site | $150,000 |

Estimated Total Cost: $1,010,000

Suggested Laboratories

Timeline

• Months 1-6: Protocol finalization, site preparation, assay validation
• Months 7-30: Participant recruitment and follow-up
• Months 31-36: Data analysis, biomarker panel development, publication

Expected Outcomes

Primary Endpoints

• Develop validated biomarker panel achieving ≥90% sensitivity/specificity for PSP vs PD
• Establish baseline biomarker thresholds predicting rapid progression
• Identify biomarkers correlating with therapeutic response

Secondary Endpoints

• Characterize biomarker trajectories over disease progression
• Validate imaging biomarkers against neuropathology (autopsy cases)
• Create clinically implementable biomarker algorithm

Biomarker Panel Deliverable

• Blood-based screening test (NfL + p-tau)
• Confirmatory MRI protocol
• Optional tau PET for clinical trial enrichment

Scoring

| Dimension | Score (1-10) | Rationale |
|-----------|--------------|-----------|
| Scientific Value | 10 | Addresses critical gap in PSP/CBS biomarker field |
| Feasibility | 8 | Leverages existing assays and imaging protocols |
| Novelty | 9 | First comprehensive multimodal biomarker validation |
| Disease Impact | 10 | Enables earlier diagnosis and better clinical trials |
| Reach | 9 | Benefits all PSP/CBS patients (60K US, 120K EU) |
| Cost Efficiency | 7 | High cost but addresses multiple needs |
| Time Efficiency | 7 | 36 months reasonable for longitudinal study |
| Evidence Base | 8 | Strong preliminary data for candidate biomarkers |
| Addresses Uncertainty | 10 | Tests critical diagnostic and prognostic questions |
| Translation Potential | 10 | Clear path to clinical implementation |

Total Score: 88 × weight normalization = ~125/140

Related Pages

• [Biomarkers for Progressive Supranuclear Palsy](/biomarkers/progressive-supranuclear-psp-biomarkers)
• [Biomarkers for Corticobasal Degeneration](/biomarkers/corticobasal-degeneration-biomarkers)
• [CSF Biomarkers for CBS/PSP](/biomarkers/cbs-psp-csf-biomarkers)
• [Plasma Biomarkers for CBS/PSP](/biomarkers/cbs-psp-plasma-biomarkers)
• [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp)
• [MRI Atrophy Patterns in CBS/PSP](/biomarkers/mri-atrophy-cbs-psp)
• [CBS/PSP Genetic Architecture](/mechanisms/cbs-psp-genetic-architecture)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)

References